RxDoctor Payments Data

Simone Bailey-Brown, MD

Cardiovascular Disease · Rochester, NYNPI 1114183282

Payments from drug & device makers

$48,518in general payments, 2019–2025

Across 53 payments — averaging $915.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$48K
  • Astellas Pharma US Inc$107
  • Pfizer$89
  • Amarin Pharma, Inc.$67
  • Boston Scientific$59
  • Novartis$34
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$42183%
  • Education$8817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$48,518 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$184,137
Medicare patients
516
Services billed
2,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$94,116
EntrestoSacubitril/Valsartan27$28,421
Repatha SureclickEvolocumab25$26,498
XareltoRivaroxaban18$18,594
FarxigaDapagliflozin Propanediol19$18,288
VascepaIcosapent Ethyl14$9,162
BrilintaTicagrelor12$6,792
Metoprolol Succinate174$2,090
Rosuvastatin Calcium105$1,828
Ezetimibe64$1,786
Atorvastatin Calcium157$1,323
Losartan Potassium127$1,131
Chlorthalidone31$694
Carvedilol79$621
Amiodarone Hcl24$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$94,11677 claims
NovartisEntresto$34$28,42127 claims
AstraZenecaFarxiga, Brilinta$12$25,07931 claims
Johnson & JohnsonXarelto$12$18,59418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →